Pipeline

Hy BioPharma has acquired the worldwide exclusive license to the intellectual property and marketing rights for Hypericin and other perylene-quinone derivatives related to Hypericin.


The following table summarizes the development status of Hy BioPharma’s pipeline products:

	Preclinical	Phase I	Phase II	Phase III
Topical
CTCL
Mild-moderate Psoriasis
Oral
Brain cancer (Glioblastoma)
Moderate-severe Psoriasis
Inflamatory Bowel Diseases
Ocular Diseases (antiangiogenesis)____________
Multiple Sclerosis (HBP-412)